X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs UNICHEM LAB - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA UNICHEM LAB ALEMBIC PHARMA/
UNICHEM LAB
 
P/E (TTM) x 19.9 23.9 83.2% View Chart
P/BV x 5.2 2.3 231.4% View Chart
Dividend Yield % 0.9 1.1 79.6%  

Financials

 ALEMBIC PHARMA   UNICHEM LAB
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
UNICHEM LAB
Mar-17
ALEMBIC PHARMA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs792320 247.5%   
Low Rs443221 200.5%   
Sales per share (Unadj.) Rs167.0167.2 99.9%  
Earnings per share (Unadj.) Rs38.212.0 319.1%  
Cash flow per share (Unadj.) Rs42.016.9 248.0%  
Dividends per share (Unadj.) Rs4.003.00 133.3%  
Dividend yield (eoy) %0.61.1 58.4%  
Book value per share (Unadj.) Rs84.9117.0 72.5%  
Shares outstanding (eoy) m188.5290.88 207.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.6 228.5%   
Avg P/E ratio x16.222.6 71.5%  
P/CF ratio (eoy) x14.716.0 92.0%  
Price / Book Value ratio x7.32.3 314.7%  
Dividend payout %10.525.1 41.8%   
Avg Mkt Cap Rs m116,38324,578 473.5%   
No. of employees `000NA5.2 0.0%   
Total wages/salary Rs m4,2142,487 169.4%   
Avg. sales/employee Rs ThNM2,928.3-  
Avg. wages/employee Rs ThNM479.4-  
Avg. net profit/employee Rs ThNM209.4-  
INCOME DATA
Net Sales Rs m31,48715,195 207.2%  
Other income Rs m55110 50.0%   
Total revenues Rs m31,54215,305 206.1%   
Gross profit Rs m10,0601,788 562.7%  
Depreciation Rs m722452 159.8%   
Interest Rs m3734 109.2%   
Profit before tax Rs m9,3561,413 662.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,160326 663.0%   
Profit after tax Rs m7,1941,087 662.0%  
Gross profit margin %31.911.8 271.5%  
Effective tax rate %23.123.1 100.1%   
Net profit margin %22.87.2 319.5%  
BALANCE SHEET DATA
Current assets Rs m15,0666,426 234.4%   
Current liabilities Rs m7,6743,917 195.9%   
Net working cap to sales %23.516.5 142.2%  
Current ratio x2.01.6 119.7%  
Inventory Days Days6768 98.9%  
Debtors Days Days4177 52.8%  
Net fixed assets Rs m8,2377,410 111.2%   
Share capital Rs m377182 207.4%   
"Free" reserves Rs m15,41610,454 147.5%   
Net worth Rs m16,00510,636 150.5%   
Long term debt Rs m04 0.0%   
Total assets Rs m24,59415,258 161.2%  
Interest coverage x255.242.9 594.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.31.0 128.6%   
Return on assets %29.47.3 400.4%  
Return on equity %44.910.2 439.9%  
Return on capital %58.713.6 431.7%  
Exports to sales %55.724.1 231.1%   
Imports to sales %10.44.9 210.8%   
Exports (fob) Rs m17,5513,666 478.8%   
Imports (cif) Rs m3,283752 436.8%   
Fx inflow Rs m17,8115,298 336.1%   
Fx outflow Rs m5,3180-   
Net fx Rs m12,4935,298 235.8%   
CASH FLOW
From Operations Rs m9,304683 1,361.4%  
From Investments Rs m-3,105-1,316 236.0%  
From Financial Activity Rs m-1,959592 -330.8%  
Net Cashflow Rs m4,240-40 -10,626.6%  

Share Holding

Indian Promoters % 74.1 50.1 147.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 15.1 19.2%  
FIIs % 9.1 3.0 303.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 31.7 43.8%  
Shareholders   49,328 20,176 244.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Extends Losses; Pharma Stocks Top Losers(Closing)

After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


May 21, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS